Siliq for psoriasis maintains clearance, improved quality of life through 5 years

Siliq demonstrated skin clearance and improved quality of life in adult patients with moderate to severe plaque psoriasis with no new safety signals emerging throughout 5 years of treatment in a phase 2, open-label extension study.

“A number of patients achieved clear or almost clear skin within the first 2 weeks of treatment, with further improvements occurring through week 12,” Mark G. Lebwohl, MD, professor and system chair in the department of dermatology of Icahn School of Medicine at Mount Sinai, and colleagues wrote. “Maintenance of efficacy was observed through week 264 when patients had been off treatment for 6 weeks.”